Image Credit: STAT News
STAT+: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two new clinical trials.